Frontlight ResearchEarly access
Active, not recruitingNo phase
Artoss Prospective Spine Registry Outcomes
Key facts
- Who runs it
- Artoss Inc.
- Where
- Bethesda, Biloxi, Chandler, Hartford, San Diego, and Tempe, United StatesSee the 6 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 330 people enrolled
- Started
- 3 Aug 2020
- Ended
- 30 Jun 2025
- Type of study
- Observational
- Treatments tested
- NanoBone Bone Graft Substitute
- Record updated
- 12 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patient aged 18 years or older
- Patient is diagnosed with a degenerative spine disorder requiring spinal fusion, has failed conservative treatment, and has decided to undergo surgery
- The surgeon has determined that a NanoBone product is or was clinically indicated, and will use or have used the product as a stand-alone bone graft substitute or in combination with local autograft only (no iliac crest harvesting, other BGS, or biologic {defined as containing growth factors, cytokines, proteins, or cells} used)
- Patient capable of understanding the content of the Informed Consent Form
- Patient willing and able to participate in the registry protocol including SOC follow-up visits and clinical evaluations
- Patient who has agreed to participate in the registry by providing consent according to the applicable local law and the Declaration of Helsinki
Who cannot take part
- Uncooperative patients who cannot or will not follow post-operative instruction, including individuals who abuse drugs and/or alcohol
- Uncontrolled diabetes
- Severe degenerative disease (other than degenerative disc disease)
- Existing acute or chronic infections, especially at the site of the operation
- Inflammatory bone disease such as osteomyelitis
- Malignant tumors
- Hypercalcemia, abnormal calcium metabolism
- Severely impaired renal function
- Patients who are or plan to become pregnant
Where in United States
- OrthoBethesdaBethesda, United States
- Sam Shamsnia MD NeurosurgeryBiloxi, United States
- OrthoArizonaChandler, United States
- Hartford Health CareHartford, United States
- Senta ClinicSan Diego, United States
- Sonoran SpineTempe, United States
About the trial
What the trial wants to find out
This prospective registry was designed as an observational study to ascertain how commercially available NanoBone Bone Graft is being used by surgeons performing spinal fusion as well as determining relevant patient outcomes.
The group in the trial
- Spine Fusion using NanoBone
All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
Treatment: NanoBone Bone Graft Substitute
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter Prospective Registry to Evaluate Use and Outcomes of NanoBone® Bone Graft Substitute in Spinal Fusion Surgery
- Record updated
- 12 February 2025